COMPLEMENT-MEDIATED KIDNEY DISEASE
Clinical trials for COMPLEMENT-MEDIATED KIDNEY DISEASE explained in plain language.
Never miss a new study
Get alerted when new COMPLEMENT-MEDIATED KIDNEY DISEASE trials appear
Sign up with your email to follow new studies for COMPLEMENT-MEDIATED KIDNEY DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug ADX-038 aims to control rare kidney diseases
Disease control Recruiting nowThis study tests a new drug called ADX-038 in 45 adults with kidney diseases caused by an overactive complement system (part of the immune system), including IgA nephropathy and C3G. The goal is to see if the drug is safe and can help control the disease. Participants must have a…
Matched conditions: COMPLEMENT-MEDIATED KIDNEY DISEASE
Phase: PHASE2 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 12, 2026 13:44 UTC
-
New drug CMS-D017 takes first steps in human testing
Knowledge-focused Recruiting nowThis early-stage study tests a new drug called CMS-D017 in 88 healthy adults to see if it is safe and how the body processes it. The drug is being developed for two rare blood and kidney diseases. Participants receive either the drug or a placebo, and researchers monitor side eff…
Matched conditions: COMPLEMENT-MEDIATED KIDNEY DISEASE
Phase: PHASE1 • Sponsor: Shenzhen Kangzhe Biotechnology Co., Ltd. • Aim: Knowledge-focused
Last updated May 17, 2026 03:40 UTC